Advancing novel bispecific antibodies to treat cancer.
Leveraging our technology, unique insights and capabilities to develop bispecifics with superior profiles.
We are developing programs to address specific issues in currently available therapies and overcome major hurdles in novel classes of molecules.
Our team’s expertise and insights position us well to usher in a new wave of novel bispecific antibody therapies.